Trademark Overview
On Thursday, November 14, 2024, a trademark application was filed for SWITCH-BLOCKER with the United States Patent and Trademark Office. The USPTO has given the SWITCH-BLOCKER trademark a serial number of 98853592. The federal status of this trademark filing is PUBLICATION/ISSUE REVIEW COMPLETE as of Thursday, October 16, 2025. This trademark is owned by Aegea Biotechnologies, Inc.. The SWITCH-BLOCKER trademark is filed in the Pharmaceutical Products, Medical Instrument Products, Computer & Software Services & Scientific Services, and Medical & Beauty Services & Agricultural Services categories with the following description:
Health assessment services; medical analysis services for diagnostic and treatment purposes provided by medical laboratories; and consulting services in the fields of diagnostic medical testing and treatment of diseases
Medical, scientific and clinical research in the fields of diagnostics, genomics, next generation sequencing (NGS) and therapeutics, molecular diagnostics for the detection of DNA and RNA targets of interest, Sanger sequencing, NGS, capillary electrophoresis, mass-spectral analysis, and microarray analysis
Medical diagnostic apparatus and instruments for testing DNA and RNA and for diagnostic testing for the interrogation of DNA and RNA nucleic acids for any disease or condition where it is desired to detect specific nucleic acids or derivative thereof, namely, cancer, an infectious disease, inherited genetic disease, somatic aberration, and rejection of transplanted organs
Medical diagnostic reagents and assays for testing of bodily fluids for use in detection of any disease or condition where it is desired to detect specific nucleic acids or derivatives thereof, namely, cancer, infectious disease, inherited genetic disease, somatic aberration, and rejection of transplanted organs; drug testing kits comprised of medical diagnostic reagents and assays that test for the presence of gene events, namely, mutations, single nucleotide polymorphisms (SNP's) and other disease biomarkers, translocations, deletions, gene copy number changes, RNA expression levels, and biomarkers specific to disease conditions; drug testing kits comprised of medical diagnostic reagents and assays, test strips, test patches, and test media for testing of bodily fluids for use in detection of any disease or condition where it is desired to detect specific nucleic acids or derivatives thereof, namely, cancer, infectious disease, inherited genetic disease, somatic aberration, and rejec...
